| Drug General Information |
| Drug ID |
D0P3RF
|
| Former ID |
DIB019426
|
| Drug Name |
compound 3
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Formula |
C14H11BrN4O3S
|
| InChI |
InChI=1S/C26H26N6O2/c1-31-10-12-32(13-11-31)21-5-3-4-19-25(21)28-26(27-19)24-18-8-6-16(14-20(18)29-30-24)17-7-9-22(33)23(15-17)34-2/h3-9,14-15,33H,10-13H2,1-2H3,(H,27,28)(H,29,30)
|
| InChIKey |
KKMLIJHOUUKCSW-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
mRNA of PKC-zeta |
Target Info |
Inhibitor |
[1]
|
|---|
| Cell division protein kinase 2 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Rap1 signaling pathway
|
|
Chemokine signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Hippo signaling pathway
|
|
Tight junction
|
|
Platelet activation
|
|
Insulin signaling pathway
|
|
Type II diabetes mellitushsa04068:FoxO signaling pathway
|
|
Cell cycle
|
|
Oocyte meiosis
|
|
p53 signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Hepatitis B
|
|
Measles
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Prostate cancer
|
|
Small cell lung cancer
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
Angiogenesis
|
|
EGF receptor signaling pathway
|
|
Endothelin signaling pathway
|
|
FGF signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
VEGF signaling pathway
|
|
Wnt signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
Histamine H1 receptor mediated signaling pathway
|
|
Oxytocin receptor mediated signaling pathway
|
|
Thyrotropin-releasing hormone receptor signaling pathwayP00059:p53 pathway
|
|
p53 pathway feedback loops 2
|
|
Pathway Interaction Database
|
RhoA signaling pathway
|
|
Insulin Pathway
|
|
Noncanonical Wnt signaling pathway
|
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
CDC42 signaling events
|
|
Thromboxane A2 receptor signaling
|
|
IL1-mediated signaling events
|
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
CXCR4-mediated signaling events
|
|
IGF1 pathway
|
|
TNF receptor signaling pathway
|
|
IL2 signaling events mediated by PI3K
|
|
Ceramide signaling pathway
|
|
p75(NTR)-mediated signaling
|
|
amb2 Integrin signaling
|
|
ErbB1 downstream signaling
|
|
Neurotrophic factor-mediated Trk receptor signaling
|
|
Nephrin/Neph1 signaling in the kidney podocyte
|
|
Insulin-mediated glucose transport
|
|
Regulation of Ras family activationsmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by PRL
|
|
p73 transcription factor network
|
|
E2F transcription factor network
|
|
ATR signaling pathway
|
|
mTOR signaling pathway
|
|
IL2-mediated signaling events
|
|
FoxO family signaling
|
|
FOXM1 transcription factor network
|
|
BARD1 signaling events
|
|
p53 pathway
|
|
Regulation of retinoblastoma protein
|
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
|
Reactome
|
GPVI-mediated activation cascade
|
|
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
|
|
VEGFR2 mediated cell proliferationR-HSA-1538133:G0 and Early G1
|
|
Activation of ATR in response to replication stress
|
|
Regulation of APC/C activators between G1/S and early anaphase
|
|
SCF(Skp2)-mediated degradation of p27/p21
|
|
Senescence-Associated Secretory Phenotype (SASP)
|
|
DNA Damage/Telomere Stress Induced Senescence
|
|
Processing of DNA double-strand break ends
|
|
G2 Phase
|
|
Orc1 removal from chromatin
|
|
Cyclin E associated events during G1/S transition
|
|
Cyclin A/B1 associated events during G2/M transition
|
|
p53-Dependent G1 DNA Damage Response
|
|
Cyclin A:Cdk2-associated events at S phase entry
|
|
Meiotic recombination
|
|
Factors involved in megakaryocyte development and platelet production
|
|
WikiPathways
|
Calcium Regulation in the Cardiac Cell
|
|
Insulin Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
Wnt Signaling Pathway
|
|
Wnt Signaling Pathway and Pluripotency
|
|
MAPK Signaling Pathway
|
|
G Protein Signaling Pathways
|
|
Myometrial Relaxation and Contraction Pathways
|
|
Signaling by TGF-beta Receptor Complex
|
|
Allograft Rejection
|
|
AGE/RAGE pathway
|
|
TNF alpha Signaling Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
miRs in Muscle Cell Differentiation
|
|
IL-1 signaling pathway
|
|
GPVI-mediated activation cascade
|
|
Type II diabetes mellitusWP707:DNA Damage Response
|
|
ID signaling pathway
|
|
DNA Replication
|
|
G1 to S cell cycle control
|
|
M/G1 Transition
|
|
S Phase
|
|
Meiotic Recombination
|
|
Aryl Hydrocarbon Receptor
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Oncostatin M Signaling Pathway
|
|
Prostate Cancer
|
|
TSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Synthesis of DNA
|
|
Regulation of DNA replication
|
|
Mitotic G2-G2/M phases
|
|
Mitotic G1-G1/S phases
|
|
Factors involved in megakaryocyte development and platelet production
|
|
Cell Cycle
|
|
APC/C-mediated degradation of cell cycle proteins
|
|
Cell Cycle Checkpoints
|
|
miRNA Regulation of DNA Damage Response
|
| References |
| REF 1 | 2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor. Bioorg Med Chem Lett. 2009 Feb 1;19(3):908-11. |
|---|
